Since the beginning of the pandemic, the Grupo Oncoclínicas spared no efforts to adapt all its facilities and train its teams to face the situation as the moment demanded. After all, cancer does not wait. As challenging as it was to reconcile the management of a new disease, covid-19, with the other existing ones, it took a collective effort. “We established a protocol of procedures that is followed in all regions of the country for the safety of employees and collaborators and to guide treatments,” says Emilio Carlos de Arruda Lacerda, oncologist at the Oncology Center of Paraíba.
One of the results of these initiatives by the Group was the article published in the renowned journal JCO Global Oncology (belonging to the American Society of Clinical Oncology – ASCO), Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil. It features an analysis of 198 patients with Covid-19, registered in the database from March 29 to July 4, 2020. Among these individuals, 167 (84%) had solid tumors and 31 (16%) had hematologic neoplasms. The goal was to establish clinical determinants of mortality in a cohort of patients with cancer and Sars-CoV-2 infection in oncology practice. “It’s not because they have cancer that these patients are going to have a higher risk of dying,” says oncologist Pedro de Marchi, one of the study’s authors.